KIORA PHARMACEUTICALS, INC. Amortization of Intangible Assets
KIORA PHARMACEUTICALS, INC. (KPRX) reported Amortization of Intangible Assets of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-03-25
- KIORA PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2021-12-31 was $6.25K, a 0.00% change year-over-year.
- KIORA PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2021-09-30 was $6.25K, a 0.00% change year-over-year.
- KIORA PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2021-06-30 was $6.25K, a 0.00% change year-over-year.
- KIORA PHARMACEUTICALS, INC. amortization of intangible assets for the quarter ending 2021-03-31 was $6.25K, a 0.00% change year-over-year.
- KIORA PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- KIORA PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2024 was $15.00K, a 40.00% decline from fiscal 2023.
- KIORA PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2023 was $25.00K, a 0.00% change from fiscal 2022.
- KIORA PHARMACEUTICALS, INC. amortization of intangible assets for fiscal 2022 was $25.00K, a 0.00% change from fiscal 2021.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-25 | |||
| 2024-12-31 | $15.00K 10-K · filed 2026-03-25 | |||
| 2023-12-31 | $25.00K 10-K · filed 2025-03-25 | |||
| 2022-12-31 | $25.00K 10-K · filed 2024-03-25 | |||
| 2021-12-31 | $6.25K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $12.50K derived: sum of 2 quarters · filed 2023-03-23 | $18.75K derived: sum of 3 quarters · filed 2023-03-23 | $25.00K 10-K · filed 2023-03-23 |
| 2021-09-30 | $6.25K 10-Q · filed 2021-11-15 | $12.50K derived: sum of 2 quarters · filed 2021-11-15 | $18.75K 10-Q · filed 2021-11-15 | $25.00K derived: sum of 4 quarters · filed 2022-07-07 |
| 2021-06-30 | $6.25K 10-Q · filed 2021-08-12 | $12.50K 10-Q · filed 2021-08-12 | $18.75K derived: sum of 3 quarters · filed 2022-07-07 | $25.00K derived: sum of 4 quarters · filed 2022-07-07 |
| 2021-03-31 | $6.25K 10-Q · filed 2021-05-12 | $12.50K derived: sum of 2 quarters · filed 2022-07-07 | $18.75K derived: sum of 3 quarters · filed 2022-07-07 | $25.00K derived: sum of 4 quarters · filed 2022-07-07 |
| 2020-12-31 | $6.25K derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-07-07 | $12.50K derived: sum of 2 quarters · filed 2022-07-07 | $18.75K derived: sum of 3 quarters · filed 2022-07-07 | $25.00K 10-K/A · filed 2022-07-07 |
| 2020-09-30 | $6.25K 10-Q · filed 2021-11-15 | $12.50K derived: sum of 2 quarters · filed 2021-11-15 | $18.75K 10-Q · filed 2021-11-15 | $25.00K derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $6.25K 10-Q · filed 2021-08-12 | $12.50K 10-Q · filed 2021-08-12 | $18.75K derived: sum of 3 quarters · filed 2021-08-12 | $25.00K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $6.25K 10-Q · filed 2021-05-12 | $12.50K derived: sum of 2 quarters · filed 2021-05-12 | $18.75K derived: sum of 3 quarters · filed 2021-05-12 | $25.00K derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | $6.25K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $12.50K derived: sum of 2 quarters · filed 2021-03-25 | $18.75K derived: sum of 3 quarters · filed 2021-03-25 | $25.00K 10-K · filed 2021-03-25 |
| 2019-09-30 | $6.25K 10-Q · filed 2020-11-09 | $12.50K derived: sum of 2 quarters · filed 2020-11-09 | $18.75K 10-Q · filed 2020-11-09 | $25.00K derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $6.25K 10-Q · filed 2020-08-06 | $12.50K 10-Q · filed 2020-08-06 | $18.75K derived: sum of 3 quarters · filed 2020-08-06 | $18.75K derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $6.25K 10-Q · filed 2019-05-08 | $12.50K derived: sum of 2 quarters · filed 2020-03-04 | $12.50K derived: sum of 3 quarters · filed 2020-03-04 | $12.50K derived: sum of 4 quarters · filed 2020-03-04 |
| 2018-12-31 | $6.25K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-04 | $6.25K derived: sum of 2 quarters · filed 2020-03-04 | $6.25K derived: sum of 3 quarters · filed 2020-03-04 | $6.25K 10-K · filed 2020-03-04 |
| 2018-09-30 | $0.00 10-Q · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | $0.00 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $0.00 10-Q · filed 2019-08-08 | $0.00 10-Q · filed 2019-08-08 | ||
| 2017-12-31 | $0.00 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |